Zenas BioPharma (ZBIO) Cash from Financing Activities (2023 - 2026)

Zenas BioPharma's Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $433.5 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 437757.58% year-over-year to $433.5 million in Q1 2026; TTM through Mar 2026 was $648.7 million, a 56.81% increase from a year earlier, with the FY2025 full-year figure at $215.3 million, down 47.87% from the prior year.
• Cash from Financing Activities rose to $433.5 million in Q1 2026 per ZBIO's latest filing, from $140.8 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $433.5 million in Q1 2026 and bottomed at -$614000.0 in Q1 2024.
• The 4-year median for Cash from Financing Activities is $37.2 million (2024), against an average of $106.2 million.
• Across the five-year window, Cash from Financing Activities tumbled 99.03% in 2025 and jumped 437757.58% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at $50000.0 in 2023, then surged by 3606.0% to $1.9 million in 2024, then surged by 7500.81% to $140.8 million in 2025, then jumped by 207.77% to $433.5 million in 2026.
• Per Business Quant, the three latest ZBIO Cash from Financing Activities figures stand at $433.5 million (Q1 2026), $140.8 million (Q4 2025), and $72.6 million (Q3 2025).